Michelle Olga Patricia Visser is the Inventor of Virodene^® P058

It was her research into methods of cryopreservation at the University of Pretoria’s Thoracic Surgery Department, which led Ms Visser to observe and record that DMF, the main ingredient of Virodene^® P058, had anti-viral properties.

Cryopreservation is the study of freezing organs to temperatures as low as 196 degrees centigrade, storing them at these temperatures, and then thawing and reviving them to full function. She also developed a novel cryo-protectant solution, key to achieving these objectives. However, it was during the post thawing examination that she noted a lack of viral and bacterial presence.

Further research revealed that polar compounds, including DMF, demonstrated antiviral properties, thereby confirming her observations. She also noted from these publications that workmen exposed to DMF daily, seldom suffered from influenza or viral cancers.

Ms Visser extrapolated that DMF’s effectiveness may extend to cover the viral activities relating to the HIV/AIDS virus, based on the extensive, documented research available.

Virodene^® P058 is defined as a transdermal delivery device containing 7.06g of spectograde N, N Dimethylformamide(DMF).

DMF is a bi-polar solvent excellent differentiation properties and a small molecular size. These physical properties make it an ideal medium for transdermal uptake.

The Drug Delivery System (patch) was developed in conjunction with Prof. Hugo Dürrheim, Head of the Pretoria Technikon Pharmaceutical Division, and Mr. Eugene Olivier a Transdermal Pharmacologist.

Dr. Gerald Kennedy Jr. from du Pont Chemicals assisted in the establishment of a safe dose of Virodene^® P058 for use in Humans. Using data obtained from their own in-house research into DMF over many years, a dose of 14.12g(two Virodene^® P058 patches) was suggested.

The drug formulation and the method of application have been patented